脂蛋白在肝细胞癌发生发展中的作用及其靶向治疗研究进展  

Progress in roles and targeted therapy of lipoproteins in the development of hepatocellular carcinoma

作　　者：王一凡 孙立 WANG Yifan;SUN Li(New Drug Screening Center,Institute of Pharmaceutical Sciences,China Pharmaceutical University,Nanjing 210009,China)

机构地区：[1]中国药科大学药物科学研究院新药筛选中心,江苏南京210009

出　　处：《中国药理学与毒理学杂志》2023年第11期879-884,共6页Chinese Journal of Pharmacology and Toxicology

摘　　要：肝细胞癌(肝癌,HCC)是一种肝恶性肿瘤,同时也是一种代谢性疾病。脂蛋白作为一种大分子复合物,参与体内脂质代谢过程,调控脂质稳态。当肝细胞受损时,脂蛋白代谢紊乱,脂质稳态失衡,过量脂质积累,加速肝细胞癌变;癌变的肝细胞表面过度表达脂蛋白受体,激活增殖相关信号通路,加速HCC进展。脂蛋白及其受体在HCC发生发展中的作用是目前研究热点,相关药物主要分为前蛋白转化酶枯草杆菌蛋白酶/Kexin-9抑制剂和他汀类药物两大类。本文从HCC发生发展及HCC治疗药物现状等方面综述脂蛋白对HCC进展的作用,为靶向脂蛋白治疗HCC提供依据。Hepatocellular carcinoma(HCC)is a malignant tumor of the liver and a metabolic disease.As a macromolecular complex,lipoprotein participates in the process of lipid metabolism in vivo and regulates lipid homeostasis.When hepatocytes are damaged,lipoprotein metabolism is disturbed,lipid homeostasis becomes imbalanced,and excess lipid accumulates,accelerating hepatocellular carcinoma,while overexpression of lipoprotein receptors on the surface of already cancerous hepatocytes acti-vates proliferation-related signaling pathways,accelerating the progression of HCC.The role of lipopro-teins and their receptors in the development of HCC remains a hot spot,and the related drugs are mainly categorized into proprotein convertase subtilisin/kexin type 9 inhibitors and statins.This paper reviews the role of lipoproteins in HCC progression in terms of HCC development and the current status of HCC therapeutic drugs,and provides data for targeting lipoproteins in the treatment of HCC.

关 键 词：肝细胞癌 脂蛋白 脂代谢 

分 类 号：R735.7[医药卫生—肿瘤]